Literature DB >> 7106170

Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

M I Nilsson, E Anggård, J Holmstrand, L M Gunne.   

Abstract

Deuterated methadone (M-d3) and GCMS were used to study the pharmacokinetics of methadone (M) during the induction stage of methadone maintenance treatment (MMT). A pulse dose of M-d3 was given on Days 1 and 25 of two dosage regimens, one with a continuous 30 mg dose (n = 6), and the other with 30 mg for 10 days, followed by 60 mg as the maintenance dose (n = 6). Plasma and urinary levels of M and M-d3 were measured throughout and plasma half-lives, oral bioavailabilities and volumes of distribution were calculated from the data of Days 1-2 and 24-26. The oral bioavailability of a methadone solution was found to be between 81 and 95%: elimination half-life in the beta-phase varied between 19 and 58 h; the volume of distribution was 4.1 +/- 0.65 l/kg; and total body clearance of M was 54-195 ml/min and its renal clearance 3.4-34 ml/min. A consistent finding was a lower urinary pH and increased renal clearance during the first month of treatment. The shorter elimination half-lives in those patients probably caused unacceptably high fluctuation in the body content of M during the 24 h dosage interval, and may have interfered therefore, with its therapeutic effectiveness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7106170     DOI: 10.1007/BF00548404

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

2.  Plasma levels and symptom complaints in patients maintained on daily dosage of methadone hydrochloride.

Authors:  W H Horns; M Rado; A Goldstein
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

3.  Effect of oral administration of methadone on hepatic microsomal mixed function oxidase activity in mice.

Authors:  L W Masten; G R Peterson; A Burkhalter; E L Way
Journal:  Life Sci       Date:  1974-05-01       Impact factor: 5.037

4.  The levels of methadone in the plasma in methadone maintenance.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

5.  Disposition of methadone in man after a single oral dose.

Authors:  C E Inturrisi; K Verebely
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

6.  The effect of diazepam on the metabolism of methadone by the liver of methadone-dependent rats.

Authors:  T C Spaulding; L Minium; A N Kotake; A E Takemori
Journal:  Drug Metab Dispos       Date:  1974 Sep-Oct       Impact factor: 3.922

7.  Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses.

Authors:  G D Bellward; P M Warren; W Howald; J E Axelson; F S Abbott
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

8.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

9.  Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.

Authors:  E Anggård; M I Nilsson; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

10.  Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method.

Authors:  U Meresaar; M I Nilsson; J Holmstrand; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  22 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

Review 3.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  A comparison of the effects of a macrobiotic diet and a Western diet on drug metabolism and plasma lipids in man.

Authors:  P S Wissel; M Denke; C E Inturrisi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio.

Authors:  D W Boulton; P Arnaud; C L DeVane
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

7.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.

Authors:  Monica Rodriguez; M Angeles Carlos; Ignacio Ortega; Elena Suarez; Rosario Calvo; John C Lukas
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Effect of urinary pH on the disposition of methadone in man.

Authors:  M I Nilsson; E Widerlöv; U Meresaar; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.